TANGO THERAPEUTICS INC (TNGX)
US87583X1090 - Common Stock
We assign a fundamental rating of 3 out of 10 to TNGX. TNGX was compared to 573 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TNGX as it has an excellent financial health rating, but there are worries on the profitability. TNGX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year TNGX has reported negative net income.
In the past year TNGX has reported a negative cash flow from operations.
In the past 5 years TNGX always reported negative net income.
TNGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TNGX's Return On Assets of -30.54% is fine compared to the rest of the industry. TNGX outperforms 67.25% of its industry peers.
TNGX has a better Return On Equity (-47.03%) than 68.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.54% | ||
| ROE | -47.03% | ||
| ROIC | N/A |
ROA(3y)-20.57%
ROA(5y)N/A
ROE(3y)-33.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for TNGX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNGX has been increased compared to 1 year ago.
There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 3.31 indicates that TNGX is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.31, TNGX is doing good in the industry, outperforming 74.82% of the companies in the same industry.
TNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.31 |
ROIC/WACCN/A
WACC10.21%
2.3 Liquidity
A Current Ratio of 7.49 indicates that TNGX has no problem at all paying its short term obligations.
The Current ratio of TNGX (7.49) is better than 70.07% of its industry peers.
A Quick Ratio of 7.49 indicates that TNGX has no problem at all paying its short term obligations.
TNGX has a better Quick ratio (7.49) than 70.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.49 | ||
| Quick Ratio | 7.49 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 5.79% over the past year.
TNGX shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.13%.
EPS 1Y (TTM)5.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.35%
Revenue 1Y (TTM)26.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%36.15%
3.2 Future
TNGX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -10.08% yearly.
The Revenue is expected to grow by 21.34% on average over the next years. This is a very strong growth
EPS Next Y-23.06%
EPS Next 2Y-16.27%
EPS Next 3Y-11.5%
EPS Next 5Y-10.08%
Revenue Next Year9.54%
Revenue Next 2Y-10.23%
Revenue Next 3Y-8.6%
Revenue Next 5Y21.34%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
TNGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TNGX's earnings are expected to decrease with -11.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.27%
EPS Next 3Y-11.5%
5. Dividend
5.1 Amount
No dividends for TNGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TANGO THERAPEUTICS INC
NASDAQ:TNGX (9/16/2024, 3:06:02 PM)
9.435
-1.06 (-10.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.01B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.54% | ||
| ROE | -47.03% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.49 | ||
| Quick Ratio | 7.49 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)5.79%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-23.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)26.13%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y